Maurer H R, Hassan H T
Institut für Pharmazie, Freie Universität Berlin, Germany.
Leuk Lymphoma. 1993 Mar;9(4-5):305-13. doi: 10.3109/10428199309148527.
Current concepts of immunotherapeutic approaches in leukemias and lymphomas using activated cytotoxic lymphocytes and macrophages are briefly reviewed. Defective cellular immunocytotoxic activities and effects of interleukins and chemotherapeutic drugs thereupon are discussed. In vitro assays to measure lymphokine-activated killer (LAK) and natural killer (NK) cell activities suffer from various problems, depending on the quality of the endpoints. Our clonogenic microassay for LAK cell activity, using agar-containing glass capillaries, avoids some of the potential artifacts and offers several advantages that are discussed. As an example the stimulatory effect of low mafosfamide concentrations on the LAK cell activity versus K562 human myeloid leukemia cells is demonstrated. Thus, our clonogenic LAK microassay provides a valid tool for preclinical screening of immunomodulatory agents.
本文简要回顾了目前使用活化细胞毒性淋巴细胞和巨噬细胞治疗白血病和淋巴瘤的免疫治疗方法的概念。讨论了细胞免疫细胞毒性活性缺陷以及白细胞介素和化疗药物对其的影响。根据终点指标的质量,用于测量淋巴因子激活的杀伤细胞(LAK)和自然杀伤细胞(NK)活性的体外试验存在各种问题。我们使用含琼脂的玻璃毛细管进行的LAK细胞活性克隆微试验避免了一些潜在的假象,并具有一些优势,本文对此进行了讨论。作为一个例子,展示了低浓度马法兰对LAK细胞活性相对于K562人髓系白血病细胞的刺激作用。因此,我们的克隆LAK微试验为免疫调节药物的临床前筛选提供了一个有效的工具。